Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing

The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and elimination of bilirubin. Resultant indirect hyperbilirubinemia with jaundice can cause premature discontinuation of atazanavir. Risk fo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Pharmacol Ther
Autores principales: Gammal, RS, Court, MH, Haidar, CE, Iwuchukwu, OF, Gaur, AH, Alvarellos, M, Guillemette, C, Lennox, JL, Whirl‐Carrillo, M, Brummel, SS, Ratain, MJ, Klein, TE, Schackman, BR, Caudle, KE, Haas, DW
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2015
Materias:
CPIC Guidelines
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4785051/
https://ncbi.nlm.nih.gov/pubmed/26417955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.269
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares